

Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact on Heart and Mobility Health: PANACEA-O.

NCT07500610

Status	RECRUITING
Sponsor	Cardiology Research UBC
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (5)

- Age \geq 19 years of age
- Ability to provide informed consent before any trial-related activities
- Symptomatic PAD with intermittent claudication corresponding to Fontaine stage IIa meeting all of the following:
- Stable symptoms of PAD with intermittent claudication in Fontaine stage IIa (able to walk without stopping more than 200 m/656 feet/2 blocks) for at least 90 days prior to the day of screening based on patient interview.
- Ankle-brachial-index (ABI) equal to or below 0.90 (the leg with lowest index is chosen in case of bilateral disease) or \geq 50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound, or a history of lower extremity revascularization

Exclusion (8)

- Current or previous treatment with any immunomodulating agent within 90 days prior to the day of screening.
- Walking ability limited by conditions other than PAD
- Planned orthopaedic surgery in the legs, or other major surgery known on the day of screening (surgery affecting walking ability).
- Vascular revascularisation procedure for PAD of any kind 180 days prior to the day of screening.
- Planned arterial revascularisation known on the day of screening.
- ... and 3 more (see full listing online)

Locations (1 total)

Vancouver General Hospital, Vancouver, British Columbia, Canada